Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Cyclophosphamide in Recurrent/Refractory Pediatric Malignancies
NCT00003754Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 1998
- Primary completion
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in childhood solid tumor, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Tumor Response at 3 months and Toxic Effects. Started Sep 1998; status: completed.
02
Drugs
thalidomide
03
Conditions
childhood solid tumor
Beyond the preview
Go deeper on NCT00003754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003754.